tetano
Editor, Senior Moderator
Vaccine. 2012 Oct 9. pii: S0264-410X(12)01427-2. doi: 10.1016/j.vaccine.2012.09.083. [Epub ahead of print]
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine.
Maraskovsky E, Rockman S, Dyson A, Koernig S, Becher D, Morelli AB, Barnden M, Camuglia S, Bodle J, Vandenberg K, Wang IM, Cristescu R, Loboda A, Citron M, Fontenot J, Hung D, Schoofs P, Pearse M.
Source
CSL Limited, Parkville 3052, Victoria, Australia. Electronic address: Eugene.maraskovsky@csl.com.au.
Abstract
During the 2010 Southern Hemisphere (SH) influenza season, there was an unexpected increase in the number of febrile reactions reported in the paediatric population in Australia shortly after vaccination with the CSL 2010 trivalent influenza vaccine (TIV) compared to previous seasons. A series of scientific investigations were initiated to identify the root cause of these adverse events, including in vitro cytokine/chemokine assays following stimulation of adult and paediatric whole blood, as well as mammalian cell lines and primary cells, profiling of molecular signatures using microarrays, and in vivo studies in rabbits, ferrets, new born rats and rhesus non-human primates (NHPs). Various TIVs (approved commercial vaccines as well as re-engineered TIVs) and their individual monovalent pool harvest (MPH) components were examined in these assays and in animal models. Although the scientific investigations are ongoing, the current working hypothesis is that the increase in febrile adverse events reported in Australia after vaccination with the CSL 2010 SH TIV may be due to a combination of both the introduction of three entirely new strains in the CSL 2010 SH TIV, and differences in the manufacturing processes used to manufacture CSL TIVs compared to other licensed TIVs on the market. Identification of the causal component(s) may result in the identification of surrogate assays that can assist in the formulation of TIVs to minimise the future incidence of febrile reactions in the paediatric population.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23063831
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23063831
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine.
Maraskovsky E, Rockman S, Dyson A, Koernig S, Becher D, Morelli AB, Barnden M, Camuglia S, Bodle J, Vandenberg K, Wang IM, Cristescu R, Loboda A, Citron M, Fontenot J, Hung D, Schoofs P, Pearse M.
Source
CSL Limited, Parkville 3052, Victoria, Australia. Electronic address: Eugene.maraskovsky@csl.com.au.
Abstract
During the 2010 Southern Hemisphere (SH) influenza season, there was an unexpected increase in the number of febrile reactions reported in the paediatric population in Australia shortly after vaccination with the CSL 2010 trivalent influenza vaccine (TIV) compared to previous seasons. A series of scientific investigations were initiated to identify the root cause of these adverse events, including in vitro cytokine/chemokine assays following stimulation of adult and paediatric whole blood, as well as mammalian cell lines and primary cells, profiling of molecular signatures using microarrays, and in vivo studies in rabbits, ferrets, new born rats and rhesus non-human primates (NHPs). Various TIVs (approved commercial vaccines as well as re-engineered TIVs) and their individual monovalent pool harvest (MPH) components were examined in these assays and in animal models. Although the scientific investigations are ongoing, the current working hypothesis is that the increase in febrile adverse events reported in Australia after vaccination with the CSL 2010 SH TIV may be due to a combination of both the introduction of three entirely new strains in the CSL 2010 SH TIV, and differences in the manufacturing processes used to manufacture CSL TIVs compared to other licensed TIVs on the market. Identification of the causal component(s) may result in the identification of surrogate assays that can assist in the formulation of TIVs to minimise the future incidence of febrile reactions in the paediatric population.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23063831
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23063831